The number of Chinese IVD companies exhibiting at the 2015 American Association for Clinical Chemistry Annual Meeting (AACC) & Clinical Lab Expo (CLE) was slightly down from last year, but the breadth of diagnostic products and innovations from China appears to be on the up. Hrishi Poola and Jon Chen discuss the moves China is making to become a generator of disruptive technologies and reports on the new products and the players emerging from this market

The arrival of a new generation of intraocular lenses and corneal inlays – designed to offer clearer, improved vision without the need for reading glasses – is expected to spur growth in the presbyopia market.

Another week has seen another plethora of deals between Chinese domestic players and global gene sequencing firms. Rising demand for individualized treatments and the rush for cancer immuno-therapies is propelling fast growth for the US-Chinese biotech company Crownbio, says its executive chairman Guo-Liang Yu.

The firm's ReEBOV assay, which can deliver results within 15-25 minutes, is the first rapid test and immunoassay for the Ebola virus granted an emergency use authorization by FDA.